Life (Nov 2022)

Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma

  • Ariel Berl,
  • Ofir Shir-az,
  • Noa Perk,
  • Abraham Levy,
  • Yair Levy,
  • Avshalom Shalom

DOI
https://doi.org/10.3390/life12121997
Journal volume & issue
Vol. 12, no. 12
p. 1997

Abstract

Read online

Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients’ function, cosmetic appearance and quality of life. This study describes our experience and results with total facial autologous fat grafting for treating scleroderma. It includes 14 women and 3 men with SSc, at an average age of 51.3 years who underwent 32 autologous fat grafting surgeries between 2017–2022. The surgical technique is further described and demographic and surgical data, including preoperative and postoperative measurements were analyzed. Patients who had multiple surgeries ultimately received grafts with twice the volume of fat than in the first procedure. The oral opening increased an average of 33%. All patients reported improvement in quality of life and were very satisfied with the aesthetic outcomes. The use of autologous fat grafting to treat SSc patients successfully increased oral openings and improved facial manifestations. The procedure is reproducible, safe and leads to improvement in facial manifestations and patients’ quality of life. It can be repeated over time to preserve or enhance the results.

Keywords